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Introduction: Māori are disproportionately affected by cardiovascular disease (CVD), which is the main reason for
the eight year difference in life expectancy between Māori and non-Māori. The primary care-based IMPACT
(IMProving Adherence using Combination Therapy) trial evaluates whether fixed dose combination therapy (a “polypill”)
improves adherence to guideline-based therapy compared with current care among people at high risk of CVD.
Interventions shown in trials to be effective do not necessarily reduce ethnic disparities, and may in fact widen them.
Indigenous populations with poorer health outcomes are often under-represented in trials so the effect of interventions
cannot be assessed for them, specifically. Therefore, the IMPACT trial aimed to recruit as many Māori as non-Māori to
assess the consistency of the effect of the polypill. This paper describes the methods and results of the recruitment
strategy used to achieve this.
Methods: Experienced Māori researchers were involved in trial governance throughout trial development and conduct.
The trial Steering Committee included leading Māori researchers and was committed to equal recruitment of Māori and
non-Māori. Additional funding and Māori research nurses were sought to allow home-based assessment, establishment
of the relationship between research nurse and participant, more family involvement prior to enrollment, continuity of
the research nurse-participant relationship, and acknowledgement of other Māori culturally important procedures,
interactions, language and manners. Primary care practices with high enrollment of Māori were targeted, with
over-sampling of potentially eligible Māori patients, lower thresholds for screening of Māori and 6 months continued
Māori recruitment after non-Māori recruitment had finished.
Results: A total of 257 Māori and 256 non-Māori participants were randomized. Four Māori and eight non-Māori
participants were randomized per research nurse per month. Potentially eligible Māori were more likely than non-Māori
to proceed to subsequent stages of recruitment. Differences between randomized Māori and non-Māori were evident
(e.g. Maori were less likely to have established coronary artery disease).
Conclusions: Recruitment of equal numbers of indigenous and non-indigenous participants is possible if it is prioritised,
adequately resourced and self-determination is supported.
Trial registration: The trial is registered with the Australian New Zealand Clinical Trial Registry (ACTRN12606000067572).
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As the indigenous people of New Zealand (NZ), Māori
have rights under the United Nations Declaration of the
Rights of Indigenous Peoples [1] and the Treaty of Wai-
tangi (signed between representatives of Māori and the
British Crown) [2]. These include the rights to self-
determination and health comparable to that enjoyed
by others in NZ. Despite these rights, Māori are dis-
proportionately affected by cardiovascular disease
(CVD) [3,4]. The age-standardized prevalence of CVD
in 2007 was greater among Māori (7.41%) than among
other groups (Pacific 5.68%, Indian 4.96% and the rest
of the NZ population 4.45%) [3]. Māori age- and sex-
standardized public hospitalisation rates (2003–2005)
and mortality rates (2000–2004) were approximately
twice that of non-Māori [4] and the life-expectancy of
Māori is eight years less than non-Māori, primarily
due to CVD [4,5]. Other countries also experience
inequalities in CVD between indigenous and non-
indigenous peoples [6,7].
One approach that may improve the management of
CVD is fixed dose combination therapy (a “polypill”).
The IMPACT (IMProving Adherence using Combin-
ation Therapy) trial is a NZ primary care-based ran-
domized controlled trial assessing whether a polypill of
four CVD preventive medications improves adherence
to guideline-based therapy compared with usual care,
where medications are prescribed as single tablets or
double combinations tablets only, among people with
or at high risk of CVD, and for whom all components
of the polypill are indicated [8].
Interventions shown in trials to be effective do not
necessarily reduce ethnic disparities, and may in fact
widen them. Indigenous populations with poorer health
outcomes are often under-represented in trials so the
effect of interventions cannot be assessed for them,
specifically. Therefore, the IMPACT trial aimed to
recruit as many Māori as non-Māori to assess the
consistency of the effect of the polypill [9,10]. However,
researchers have often found it challenging to recruit
sufficient numbers of indigenous participants to inter-
vention trials, including Māori [11-13] so specific strat-
egies were developed to achieve equal recruitment of
Māori and non-Māori participants.
The trial was also developed from an indigenous
rights-based perspective. Priority was therefore placed
on supporting indigenous rights to self-determination
to the extent feasible throughout the trial. Equal re-
cruitment of Māori and non-Māori was sought so that
information about Māori would be obtained to at least
the same depth and breadth as that obtained for non-
Māori. This meant oversampling of Māori who com-
prised just 14% of the total NZ population in the latest
reported Census [14]. This paper describes the methodsused to achieve equal recruitment in the IMPACT trial
and results of this recruitment strategy.
Methods
Trial governance
The trial Steering Committee included experienced
Māori researchers who were involved in every stage of
trial design and conduct. From the outset, the trial
Steering Committee made a commitment to recruit
equal numbers of Māori and non-Māori so that the
trial could assess the likely usefulness of a polypill-
based strategy to reduce inequalities between Māori
and non-Māori.
Research nurses
Research nurses were employed to undertake most trial
procedures including baseline assessments (face-to-face)
on behalf of trial primary care physicians.
Māori research nurses were sought to optimise
recruitment of Māori participants [11]. Additional
funding and research nurse time were allocated for the
recruitment of Māori participants to allow for extra
face-to-face time (face-to-face contact is essential for
Māori participants), the development of trust and rap-
port, whakawhanaungatanga (culturally-specific process
of establishing relationships with people), more family
involvement prior to enrollment and continuity of the
research nurse-participant relationship over the course
of the trial [11,15]. We estimated that twice the re-
search nurse time would be needed to recruit Māori
compared with non-Māori (estimated randomisation
rate of seven Māori and 14 non-Māori participants per
full time research nurse per month).
Primary care physicians
The trial was undertaken in 54 practices from the
Auckland and Waikato regions of NZ. The endorse-
ment of Primary Health Organisations (PHOs, organi-
sations that assist primary care physicians and other
primary care staff with business management and qual-
ity of care) in areas likely to have high enrollment of
Māori was sought. PHOs also provided opportunities
for trial researchers to discuss the trial at meetings of
primary care physicians, and identified practices with
high enrollment of Māori. Practices with high enrollment
of Māori were prioritised for invitation to participate.
Participants
Systematic searches of electronic medical records identi-
fied potentially eligible patients. Over-sampling of poten-
tially eligible Māori patients and lower thresholds for
screening of Māori were used (Table 1) although actual
trial eligibility criteria were the same for all participants
(Table 2).
Table 1 Search strategy to identify potentially eligible
participants from electronic practice records of primary
care physicians
Category Criteria Ethnicity
Risk assessment Documented 5 year CVD risk ≥ 15% All
CVD Documented history of CVD All
Prescription for glyceryl trinitrate in
last 6 months (an indicator that may
have ischaemic heart disease)
Māori only
Smoker Male smokers aged 55-69 Māori only
Female smokers aged 65-79 Māori only
Diabetes Men with diabetes aged 60-69 Māori only
Women with diabetes aged 65-79 Māori only
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records, and then directly from patients as part of the
informed consent process, according to NZ guidelines
[18]. The non-Māori group included all other ethnic
groups as recommended by NZ guidelines for ethnicity
statistics [19].
Recruitment
Primary care physicians reviewed the list of potentially
eligible patients against trial inclusion / exclusion cri-
teria. Letters of invitation were sent from the primary
care physician to their patients who were likely to be
eligible. Face-to-face written informed consenting and
baseline assessments were undertaken with a research
nurse at the practice, research venue or participant’s
home, according to the participant’s preference, with
extra time and visits allowed if longer consultation or
inclusion of family in discussion was required. Partici-
pants then attended their primary care physician with
the research nurse for final confirmation of eligibility.Table 2 Trial inclusion and exclusion criteria
Inclusion criteria
● High CVD risk (5-year CVD risk equal or greater than 15%, either on
the basis of a documented history of CVD or estimated from the NZ
modified Framingham equation [16])
● All polypill ingredients indicated
● Uncertainty whether therapy best provided as a polypill or with
usual care
● Participant able to give informed consent
Exclusion criteria
● Age under 18 years
● Age over 80 years (or over 70 years for men with no history of CVD
because the risks of aspirin may be greater than the benefits of
aspirin in this population [17])
● Contraindication to polypill component
● Congestive heart failure
● Medication change unsuitable for patientOnce confirmed, the primary care physician activated
randomisation (concealed, via a centralised computer
system). The strategies used to enhance Māori recruit-
ment are shown in Table 3.
Statistical power and sample size
We estimated that recruitment of 500 participants would
provide 89% power at 2p = 0.05 to detect a 0.25 mmol/l
difference in LDL cholesterol and a 4 mm Hg difference
in systolic blood pressure between the intervention and
control groups, assuming standard deviations around
the change from baseline of 0.8 mmol/l and 14 mm Hg,
respectively. With 500 participants there would also be
sufficient power (92%) to detect a 30% relative improve-
ment in adherence. We calculated that if 250 participants
were Māori this would confer approximately 62-69%
power at the 5% significance level to separately assess the
treatment effects outlined above.
The full trial protocol including further details on
planned statistical analyses has been published [8].
Results
Research nurses
Two Māori research nurses and one non-Māori research
nurse with extensive experience working with Māori
were employed to recruit Māori participants. Two other
non-Māori research nurses were employed for non-M
āori recruitment. On average each nurse randomized
four Māori or eight non-Māori participants per month.
Flow of participants
A total of 7461 potentially eligible patients was systemat-
ically identified from electronic practice records, 4671 of
whom were invited onto the trial, 1069 were registered,
814 consented and 513 randomized (Figure 1). The ma-
jority of assessments were undertaken in participants’
homes. The proportion of potentially eligible Māori that
progressed to each stage of recruitment was statistically
significantly greater than non-Māori (p < 0.001). Māori
were also significantly more likely to be excluded than
non-Māori (p < 0.001). The main reasons for exclusion
are listed in Table 4. Māori were more likely than non-
Māori to have a CVD risk that was too low for inclusion
(75 vs 32, p < 0.0001), to have no or incomplete labora-
tory results (49 vs 20, p < 0.0001) and to have an LDL
cholesterol that was unable to be calculated (14 vs 5,
p = 0.036). Māori recruitment continued for six months
after non-Māori recruitment had finished until equal
recruitment with non-Māori had been achieved.
Baseline characteristics of randomized participants
Randomized participants comprised Māori (n = 257,
50%), European (n = 195, 38%), Pacific (n = 47, 9%) and
Asian or Other people (n = 14, 3%). The proportion of
Table 3 Strategies for enhancing recruitment of Māori
Trial process Supporting indigenous self-determination Making equal recruitment a priority
Trial governance - Experienced Māori researchers in trial governance
and involved in every stage of trial design and
conduct
- Explicit commitment to equal recruitment
by Steering Committee from outset
Trial staff - Employment of Māori research nurses or research
nurses with significant experience working
with Māori
- Ensuring enough funding for research nurses
to have extra time to undertake recruitment
in a culturally appropriate manner
Trial practices - Targeting practices with high numbers of
enrolled Māori
Screening of potential participants - Over-sampling and broad search strategy to
optimise recruitment of Māori onto the trial
- Longer recruitment duration
Contact with participants - Face-to-face contact (at location of participant’s
choosing)
- Whakawhaungatanga
- Development of trust and rapport (may require
multiple visits)
- Continuity of research nurse staff and
relationship between nurse and participant
- Family involvement before enrollment and
on-going
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amongst non-Māori (46 vs 27%, p < 0.001) (Table 5).
Māori participants were less likely than non-Māori to
have a history of CVD (32 vs 59%, p < 0.0001) or a his-
tory of coronary artery disease (23 vs 49%, p < 0.0001).
Type 2 diabetes was more common amongst Māori than
non-Māori participants (48 vs 32%, P = 0.0002).
Baseline self-reported adherence to the combination of
antiplatelet, cholesterol-lowering therapy and at least
two antihypertensives (“quadruple therapy”) was higherFigure 1 Flow of participants by ethnicity, numbers (%^).
*Difference between percentage of Māori and percentage of non-
Māori statistically significant, p<0.001. ^Percentage calculated using
number potentially eligible as denominator.amongst non-Māori than Māori participants (51 vs 37%,
p = 0.0011).
Discussion
Despite previous low levels of Māori participation in
clinical trials, equal numbers of Māori and non-Māori
participants were recruited in this study among patients
at high risk of CVD. The trial will therefore be able to
assess the consistency of the effects of the polypill in
Māori compared with non-Māori, though it is not ad-
equately powered to separately assess these effects in
Māori and non-Māori.
The two key aspects to achieving the recruitment tar-
get were supporting indigenous self-determination and
making equal recruitment a priority. Indigenous self-
determination was supported by: having experienced
Māori researchers in trial governance; employment of
Māori research nurses or research nurses with signifi-
cant experience working with Māori; and ensuring that
contact with participants was culturally appropriate.
Equal recruitment was prioritised by: having a commit-
ment to this by the trial Steering Committee; obtaining
sufficient extra funding for additional research nurse
time required to recruit Māori; targeting practices with
high Māori populations; over-sampling and broadening
the search strategy to identify potentially eligible Māori;
and extending recruitment duration for Māori. It is
also likely that perceived acceptability of the polypill to
Māori contributed to recruitment onto the trial.
Once Māori were identified as potentially eligible from
electronic practice records, they were statistically
Table 4 Main reason for exclusion from trial after consent
obtained (Māori, non-Māori)
Main reason Māori Non-Māori
n n
CVD risk too low* 75 32
No or incomplete laboratory results* 49 20
Needs different medication(s) and/or dose(s) 23 19
LDL cholesterol unable to be calculated* 14 5
Contraindications 11 7
Medically unstable / comorbidities 7 7
Other reasons 17 15
Total 196 105
*Difference between Māori and non-Māori statistically significant, p<0.05.
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each subsequent stage of recruitment. Māori were also
more likely than non-Māori to be excluded once their
consent had been obtained, primarily due to the greater
proportion of Māori with a CVD risk that was too low
for inclusion. This is most likely because of the broader








Number (%) or mean (SD)
Age (years)* 59 (8) 64 (8) 62 (8)
Women* 117 (46%) 70 (27%) 187 (36%)
History of CVD* 83 (32%) 150 (59%) 233 (45%)
Coronary artery disease* 60 (23%) 126 (49%) 186 (36%)
Cerebrovascular disease 22 (9%) 32 (13%) 54 (11%)
Peripheral vascular disease 9 (4%) 10 (4%) 19 (4%)
Diabetes* 124 (48%) 94 (37%) 218 (42%)
Type 1* 0 12 (5%) 12 (2%)
Type 2* 124 (48%) 82 (32%) 206 (40%)
Systolic blood pressure^ (mm Hg) 142 (21) 145 (19) 144 (20)
Diastolic blood pressure^ (mm Hg)
*
85 (13) 81 (11) 83 (12)




















*Difference between Māori and non-Māori statistically significant, p<0.05.
^Measured using an automated blood pressure monitor (Omron T9P).(Table 2). Māori may have been more likely than non-M
āori to have no or incomplete laboratory results because
they were younger and less likely to have a history of
coronary artery disease. If research nurses (or other re-
search staff ) had obtained laboratory specimens directly
(rather than requiring patients to attend a community
laboratory), the trial may have been even more accessible
to Māori.
Higher triglyceride levels may explain why Māori were
more likely than non-Māori to be excluded because in
these circumstances LDL is unable to be calculated. The
differences in baseline characteristics between random-
ized Māori and non-Māori are also likely to reflect the
broader search strategy used to identify potentially eli-
gible Māori, plus the greater prevalence of type 2 dia-
betes among Māori [20].
The differences between Māori and non-Māori do not
undermine the validity of the comparison between treat-
ment groups (polypill-based care or usual care) because
participants are randomly allocated to treatment groups.
However, these differences will need to be taken into
consideration when interpreting any differences in treat-
ment effect in Māori and non-Māori.
While the trial has oversampled Māori, people from the
other major ethnic groups in the NZ population (Pacific,
Asian, European and Other) have also been included. The
proportion of Pacific people in the trial is greater than in
the general population (9 vs 6% [14]). This is most likely
because practices that were targeted by the trial for their
high Māori enrollment also had high enrollment of Pacific
people.
Self-reported adherence to quadruple therapy was lower
among Māori than non-Māori but this difference became
statistically non-significant when we stratified participants
by history of CVD, suggesting it is likely to be at least par-
tially due to the higher prevalence of CVD amongst non-
Māori participants in the trial.
Conclusions
Recruitment of equal numbers of Māori and non-Māori
participants is possible if it is prioritised, adequately
resourced and self-determination supported. Equal re-
cruitment of indigenous and non-indigenous participants
allows the assessment of the consistency of treatment ef-
fects between these groups, and therefore the potential of
interventions to not only improve health but also to re-
duce health inequalities. Differences in the characteristics
of Māori and non-Māori participants will need to be taken
into account when assessing the consistency of treatment
effects.
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